Literature DB >> 9720506

CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis.

M D Gordon1, C Corless, A A Renshaw, J Beckstead.   

Abstract

CD99, a marker for MIC-2, reacts with normal Sertoli cells and granulosa cells. We investigated CD99 expression in the development of normal ovary and testis as well as in 25 sex cord-stromal tumors (SCSTs), 7 epithelial neoplasms, and 6 germ cell tumors. Normal Sertoli cells and mature granulosa cells showed 3+ staining with CD99. Pregranulosa cells of primordial follicles were negative. All of the eight Sertoli-Leydig cell tumors were positive with antibody to CD99, with the well-differentiated tumors showing the greatest degree of staining intensity. Reactivity of 2+ to 3+ with CD99 was observed in all of the 11 granulosa cell tumors and in yolk sac components of the germ cell tumors investigated. All of the poorly differentiated carcinomas were negative with CD99. We concluded that CD99 might be a useful marker for SCSTs and that its degree of reactivity correlates with the degree of differentiation in Sertoli-Leydig cell tumors. Additionally, CD99 might aid in distinguishing granulosa cell tumors of the ovary from poorly differentiated carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720506

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  Primitive neuroectodermal tumor of ovary in a young lady, confirmed with molecular and cytogenetic results--a rare case report with a diagnostic and therapeutic challenge.

Authors:  Vikas Ostwal; Bharat Rekhi; Vanita Noronha; Ranjan Basak; Sangeeta B Desai; Amita Maheshwari; Kumar Prabhash
Journal:  Pathol Oncol Res       Date:  2012-02-05       Impact factor: 3.201

2.  Expression of CD99 in pleomorphic carcinomas of the lung.

Authors:  Seong-Ho Yoo; Jungho Han; Tae Jin Kim; Doo Hyun Chung
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

3.  Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours.

Authors:  C J Stewart; C L Nandini; J A Richmond
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

4.  Primary yolk sac tumour of the prostate mimicking small round blue cell tumour.

Authors:  H Gui; R A Kolster; M B Palmer; J S Brooks; M Zhang; M A Husson
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

5.  The human cumulus--oocyte complex gene-expression profile.

Authors:  Said Assou; Tal Anahory; Véronique Pantesco; Tanguy Le Carrour; Franck Pellestor; Bernard Klein; Lionel Reyftmann; Hervé Dechaud; John De Vos; Samir Hamamah
Journal:  Hum Reprod       Date:  2006-03-29       Impact factor: 6.918

6.  CD99 is upregulated in placenta and astrocytomas with a differential subcellular distribution according to the malignancy stage.

Authors:  Ursula Úrias; Suely K N Marie; Miyuki Uno; Roseli da Silva; Mariá M Evagelinellis; Otavia L Caballero; Brian J Stevenson; Wilson A Silva; Andrew J Simpson; Sueli M Oba-Shinjo
Journal:  J Neurooncol       Date:  2014-05-06       Impact factor: 4.130

Review 7.  Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

8.  Non-Leydig sex-cord tumors of the testis. The place of immunohistochemistry in diagnosis and prognosis. A study of twenty cases.

Authors:  Eva Compérat; Fréderique Tissier; Karine Boyé; Gonzague De Pinieux; Annick Vieillefond
Journal:  Virchows Arch       Date:  2004-04-16       Impact factor: 4.064

9.  Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma.

Authors:  Chang Ohk Sung; Young H Ko; Sanghui Park; Kihyun Kim; Wonseog Kim
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

10.  [Immunohistochemical sex cord markers. Description and use in the differential diagnosis of ovarian tumors].

Authors:  F Kommoss; D Schmidt
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.